Special Issue

Liquid Biopsy in Gastrointestinal Cancer Disease—from Bench to Beside

Message from the Guest Editors

Liquid biopsies are in the focus of current cancer research. Liquid biopsies are cancer byproducts (mainly circulating tumor cells (CTC), circulating tumor DNA (ctDNA), tumor exosomes, and tumor-educated blood platelets (TEPs)), easily accessible in blood and other body fluids, and may be foreseen as an alternative to tissue-based diagnostics, as well as gastroenterologic and radiologic screening methods. The use of liquid biopsies may lead to early detection of primary and recurrent cancer disease, to a better control of multidisciplinary therapy regimens and the early detection of therapeutic resistance. In this Special Issue, we will offer an overview of the various types of liquid biopsies currently investigated in gastrointestinal cancer disease, focus on their possible use as novel diagnostic biomarkers, and highlight their importance as one of the main future research pillars in gastrointestinal cancer disease.

Guest Editors

Dr. Georg F. Weber

Department of Surgery, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany

Dr. Christoph Kahlert

Department of Surgery, Carl Gustav Carus University Hospital Dresden, Technische Universität Dresden, Dresden, Germany

Deadline for manuscript submissions

closed (10 October 2022)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/83102

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

